Picture of Intra-Cellular Therapies logo

ITCI — Intra-Cellular Therapies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -45 cents.  The mean expectation of
fifteen analysts for the quarter was for a loss of 44 cents per
share. Wall Street expected results to range from -58 cents
to -34 cents per share.
    * Revenue rose 50.3% to $132.10 million from a year ago;
analysts
expected $135.67 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 30 cents​.
    * The company reported a quarterly loss of $28.58 million.
    * Intra-Cellular Therapies Inc shares had risen by 2.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, four analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $82.00 
This summary was machine generated from LSEG data February 23 at
03:04 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.44          -0.30          Beat
 Sep. 30 2023      -0.57          -0.25          Beat
 Jun. 30 2023      -0.59          -0.45          Beat
 Mar. 31 2023      -0.61          -0.46          Beat

Recent news on Intra-Cellular Therapies

See all news